Moving toward multi-dimensional biomarkers in cancer immunotherapy.
Sign Up to like & getrecommendations! Published in 2020 at "Chinese clinical oncology"
DOI: 10.21037/cco.2019.12.16
Abstract: The development of anti-programmed death 1 (PD1) antibodies has rapidly changed standard oncology clinical practice however only a fraction of patients benefit from these treatments and some tumor types remain unresponsive. read more here.
Keywords: biomarkers cancer; multi dimensional; dimensional biomarkers; oncology ... See more keywords